Bavarian Nordic can currently boast that it is the only firm in the world to have an approved vaccine against infectious disease monkeypox. The current outbreak has turned the spotlight onto the Danish biotech company, which can no longer keep up with demand for its vaccine.
Consequently, the production of the monkeypox vaccine has to be kicked up a gear, according Bavarian CEO Paul Chaplin, speaking to The Wall Street Journal. He says that a number of countries have requested the vaccine but that Bavarian Nordic has limited supplies left. Bavarian therefore intends to make more.